Rationally Designed LBP for the Treatment of Neurological Diseases

Time: 3:00 pm
day: Conference Day One Track B PM 1


  • Outlining IrisRx – a platform for mechanistic based LBP drug development
  • Rational selection of BL-001 strains in drugresistant epilepsy and ALS
  • Sharing results of a pilot study with BL-001 in healthy volunteers